Clinico-pathological and genomic features of HER2-low early Breast Cancer (eBC). Results of retrospective analysis of seven adjuvant trials by the Hellenic Cooperative Oncology Group (HeCOG)

2026·

S. Lakis

,

E. Tsolaki

Nikolaos Korfiatis

,

A. Goussia

,

H.P. Kourea

,

A. Batistatou

,

M. Bobos

,

K. Papadopoulou

,

A. Charchanti

,

M. Bai

,

O. Tzaida

,

K. Petraki

,

P. Arapantoni

,

T. Koletsa

,

D. Pectasides

,

A. Koutras

,

D. Kalapanida

,

F. Dimitrakopoulos

,

E. Aravantinou-Fatorou

,

N. Spathas

,

A. Psyrri

,

H. Gogas

,

F. Zagouri

,

G. Fountzilas

NCT07561346 Cite DOI

Journal Article Clinical Trial

Authors

Nikolaos Korfiatis

Professor of Data Management and Analytics

Professor of Data Management and Analytics at the Department of Informatics, Ionian University, Corfu. Senior Statistician of the Hellenic Cooperative Oncology Group (HeCOG).

---

← Brain as a site of first recurrence after adjuvant therapy for early breast cancer: Mining the Hellenic Cooperative Oncology Group database. The BRACE study 2026

Comprehensive Molecular Profiling of Advanced NSCLC in Greek Patients: A Prospective HeCOG Study 2026 →